North Korea a big problem, will deal with it very strongly: Trump

Seoul, Jun 6: South Korea on Saturday reported 51 new cases of COVID-19, mostly in the densely populated capital region, as authorities scramble to stem transmissions among low-income workers who can't afford to stay home.

The figures announced by South Korea's Centers for Disease Control and Prevention brought national totals to 11,719 workers and 273 deaths.

At least 34 of the new coronavirus cases were linked to door-to-door sellers hired by Richway, a Seoul-based health product provider.

Vice Health Minister Kim Gang-lip said the spread of the virus among Richway sellers was particularly alarming as most of them are in their 60s and 70s. He called for officials to strengthen their efforts to find and examine workplaces vulnerable to infections.

More than 120 infections have also been linked to a massive warehouse operated by Coupang, a local e-commerce giant, which has been accused of failing to properly implement preventive measures and having employees work even when sick.

South Korea was reporting around 500 new cases per day in early March due to a massive outbreak surrounding the southern city of Daegu, before officials managed to stabilize the situation with aggressive tracking and testing.

But the recent resurgence of COVID-19 in the greater capital area, where about half of South Korea's 51 million people live, is now threatening to erase some of the country's hard-won gains. It has also led to second-guessing whether officials were too quick to ease social distancing and reopen schools.

Health authorities and hospital officials on Friday participated in a table-top exercise for sharing hospital capacities between Seoul and nearby cities and ensure swift transports of patients so that a spike of cases in one area doesn't overwhelm its hospital system. 

Islamabad, Jul 3: The US embassy here in a statement on Friday said the Trump administration through the US Agency for International Development (USAID) “donated a shipment of 100 brand-new, state-of-the-art ventilators” to Pakistan.

The ventilators arrived in Karachi on July 2 and will be sent to hospitals across Pakistan.

“This donation delivers on President Donald Trump’s generous offer of these critically-needed supplies and supports Pakistan’s urgent response to the pandemic,” the embassy said.

Made in America, the ventilators are valued at about $3 million and reflect the latest in cutting-edge medical design and technology, it said.

They are compact, easily deployable, and will enable Pakistan to more effectively treat patients suffering from Covid-19.

The US-Pakistan health partnership to curb the spread of the novel coronavirus is helping to improve and expand laboratory testing, disease monitoring, case tracking, infection prevention and control and patient care, the embassy said.

The US has contributed nearly $27 million in new funding so far to this vital partnership that is growing every day. "We are also thankful for Pakistan's contribution of medical supplies to help fight coronavirus in the US," the embassy said in the statement.

Ambassador Paul Jones said, “The US stands with Pakistan in its fight against the coronavirus. These American-made ventilators will help Pakistani patients in the most acute need of medical care."

The announcement comes days after Pakistan said it had started producing locally designed ventilators.

Pakistan reported 78 more deaths from the coronavirus in the past 24 hours, raising virus-related fatalities to 4,551 while the total number of confirmed cases has increased to 221,896.

On Friday, the health authorities said 1,13,623 persons have recovered from the coronavirus, surpassing the number of active Covid-19 infections in the country for the first time.

Melbourne, Apr 10: Scientists have identified six drug candidates from more than 10,000 compounds that may help treat COVID-19.

The research, published in the journal Nature, tested the efficacy of approved drugs, drug candidates in clinical trials and other compounds.

"Currently there are no targeted therapeutics or effective treatment options for COVID-19," said Professor Luke Guddat from the University of Queensland in Australia.

"In order to rapidly discover lead compounds for clinical use, we initiated a programme of high-throughput drug screening, both in laboratories and also using the latest computer software to predict how different drugs bind to the virus," Guddat said.

The project targeted the main COVID-19 virus enzyme, known as the main protease or Mpro, which plays a pivotal role in mediating viral replication, the researchers said.

This makes it an attractive drug target for this virus, and as people don't naturally have this enzyme, compounds that target it are likely to have low toxicity, they said.

"We add the drugs directly to the enzyme or to cell cultures growing the virus and assess how much of each compound is required to stop the enzyme from working or to kill the virus. If the amount is small, then we have a promising compound for further studies," said Guddat.

After assaying thousands of drugs, researchers found of the six that appear to be effective in inhibiting the enzyme, one is of particular interest.

"We're particularly looking at several leads that have been subjected to clinical trials including for the prevention and treatment of various disorders such as cardiovascular diseases, arthritis, stroke, atherosclerosis and cancer," Guddat said.

Researchers said compounds that are already along the pipeline to drug discovery are preferred, as they can be further tested as antivirals at an accelerated rate compared to new drug leads that would have to go through this process from scratch.

"With continued and up-scaled efforts we are optimistic that new candidates can enter the COVID-19 drug discovery pipeline in the near future," Guddat said.